Omaha, NE – Streck has added CD38 to its flow cytometry controls, CD-Chex®
Plus and CD-Chex®
Plus BC.

Along with other assayed CD markers, CD38 is often used by laboratories as a prognostic marker for
leukemia. Provided assayed values save the lab time by providing established means and ranges for
these CD markers.

CD-Chex Plus and CD-Chex Plus BC are whole blood assayed controls for monitoring
immunophenotyping by flow cytometry. These products verify the accuracy and reproducibility of all the
steps involved in the process of immunophenotyping, including red blood cell lysis. The products provide
the most assayed CD markers in the industry, which include: T lymphocytes, B lymphocytes,
granulocytes, monocytes and NK cells. CD-Chex Plus CD4 Low and CD-Chex Plus BC CD4 Low offer a
depressed CD4 absolute number often indicated in patients with immunodeficiency diseases.

Compatible with most popular flow cytometry systems, CD-Chex Plus and CD-Chex Plus BC are
available in 3.0ml plastic vials with pierceable caps and offer 30-day open-vial stability and up to 90-day
closed-vial stability.

Streck offers a free Interlaboratory Quality Control program for all customers and has electronic data entry
forms for customers who utilize CD-Chex Plus and CD-Chex Plus BC. The electronic STATS® forms
facilitate data tracking and submission.

About Streck, Inc.
Streck is an industry leader in the development and manufacturing of products for clinical and research laboratories. The company’s pursuit of innovative solutions has produced an extensive list of patented products. Streck’s core technology is cell stabilization; product lines support the fields of hematology, immunology and molecular diagnostics. For more information, visit

What we offer

Upcoming Events >